Please assess the completion status of the following clinical trial:

Trial Title: LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Histologically or cytologically confirmed R/M HNSCC of the oral cavity, oropharynx, hypopharynx or larynx, not amenable for salvage surgery or radiotherapy~2. Documented progressive disease based on investigator assessment according to Response Evaluation Criteria in Solid Tumours (RECIST) following receipt of at least two cycles of cisplatin or carboplatin administered for R/M disease~3. Measurable disease according to RECIST~4. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1~Exclusion criteria:~1. Progressive disease within three months of completion of curatively intended treatment for locoregionally advanced or metastatic HNSCC~2. Any other than one previous platinum based systemic regimen given for R/M disease~3. Prior treatment with epidermal growth factor receptor (EGFR)-targeted small molecules~4. Pregnancy or breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Afatinib (BIBW 2992) (Type: EXPERIMENTAL): Once daily
- Methotrexate (Type: ACTIVE_COMPARATOR): Weekly

Based on this trial design, predict the completion outcome and termination type (if applicable).